Real-Time News FIRE FAST SIP Calculators

Easy-to-understand Financial Insights
that build Wealth.

Explore Dzambhala NodeX

CIPLA

NSE: CIPLA | BSE: 500087

Latest on CIPLA

Cipla Acquires 20% Stake in iCaltech Innovations to Boost Innovative Technology Portfolio August 26, 2025 | 8:21 p.m. IST
Cipla's ESG Rating Downgraded from 70.2 to 69.3 Due to Social and Governance Score Declines August 11, 2025 | 6:44 p.m. IST
Cipla Receives Voluntary Action Indicated Classification From USFDA After Inspection of Bommasandra Facility August 5, 2025 | 9:15 a.m. IST
Cipla Opens Special Window Until January 6, 2026, For Re-lodgement of Share Transfer Requests August 2, 2025 | 11:21 p.m. IST
Cipla Allots 2,853 Shares Under Employee Stock Options, Boosting Paid-Up Capital to ₹1,61,55,08,148 August 2, 2025 | 10:48 p.m. IST
Cipla Secures ESG Rating of 60, Highlighting Commitment to Sustainability and Governance July 29, 2025 | 6:38 p.m. IST
Cipla Reports Q1 FY26 Revenue of ₹6,957 Cr, Achieves 10.2% Growth in Profit After Tax July 28, 2025 | 7:15 p.m. IST
Cipla Reports Q1 FY2025 Financial Results With ₹10.52 Cr Net Profit, Recovering From Previous Loss July 27, 2025 | 12:11 a.m. IST
Cipla Reports Q1FY26 Revenue of ₹6,957 Cr and PAT of ₹1,298 Cr, Driven by Strong One India Segment Performance July 25, 2025 | 1:39 p.m. IST
Cipla Reports Q1 FY26 Earnings With ₹1,298 Cr Profit After Tax and 4% Revenue Growth to ₹6,957 Cr July 25, 2025 | 1:39 p.m. IST
Cipla Reports Q1 FY2025 Revenue of ₹6,957.47 Cr and Net Profit of ₹1,291.61 Cr Amid Ongoing Legal Challenges July 25, 2025 | 1:29 p.m. IST
Cipla Reports Q1 FY2025 Revenue of ₹6,957.47 Cr and Net Profit of ₹1,291.61 Cr Amid Ongoing Litigation Over ₹2,011 Cr Claims July 25, 2025 | 1:28 p.m. IST
Cipla Grants 5,264 Stock Options and 18,178 ESARs to Employees with ₹2 Exercise Price July 25, 2025 | 1:28 p.m. IST
Cipla Reports 28% Profit Growth and Proposes ₹16 Final Dividend at 89th AGM July 23, 2025 | 7:26 p.m. IST
Cipla Acquires 20% Stake in iCaltech Innovations for ₹5 Cr to Boost Respiratory Diagnostics July 21, 2025 | 7:31 p.m. IST
Cipla's 89th AGM Sees All Resolutions Passed, Including Dividend Declaration With 99.9999% Approval July 16, 2025 | 10:33 p.m. IST
Cipla Reports Downgrade in ESG Ratings by Crisil, Core Rating Falls to 59 July 12, 2025 | 5:47 p.m. IST
Cipla Receives Crisil ESG Ratings of 64 and Core ESG Rating of 61, Highlighting Commitment to Sustainability April 24, 2025 | 7:10 p.m. IST
Cipla Informs BSE of USFDA Inspection at Medispray, Outcome Classified as Voluntary Action Indicated April 17, 2025 | 10:52 p.m. IST
Cipla Allots 23,282 Equity Shares Under Employee Stock Option Scheme, Boosting Paid-Up Capital to ₹1,61,52,80,804 April 17, 2025 | 2:49 p.m. IST
Cipla Gets USFDA Approval for Generic Cancer Drug Protein-bound Paclitaxel, Plans Launch in FY 2025-26 April 11, 2025 | 8:31 a.m. IST
Cipla To Approve Financial Results and Discuss Final Dividend in Board Meeting on 13th May 2025 April 7, 2025 | 7:56 p.m. IST
Cipla Issues 2,179 Equity Shares Under Employee Stock Option Schemes, Boosting Capital to ₹1,61,52,34,240 March 19, 2025 | 7:24 p.m. IST
Cipla's Subsidiary Sitec Labs Receives 2 USFDA cGMP Observations During Inspection February 20, 2025 | 10:58 p.m. IST
Cipla Gets USFDA Approval for Nilotinib Capsules to Treat Chronic Myeloid Leukaemia February 20, 2025 | 9:39 p.m. IST
Cipla Invests ZAR 900 Million in Cipla Medpro South Africa to Strengthen Market Presence February 18, 2025 | 9:49 p.m. IST
Cipla To Discuss Growth Strategies At Kotak Chasing Growth Conference 2025 February 18, 2025 | 10:46 a.m. IST
Cipla Allots 901 Equity Shares Under ESOS, Boosting Paid-Up Capital to ₹1,61,52,29,882 February 13, 2025 | 7:32 p.m. IST
Cipla Reports Record Q3 FY25 Revenue of ₹7,073 Cr, Achieves 28% EBITDA Margin January 31, 2025 | 8:30 p.m. IST
Cipla Publishes Unaudited Q3 FY2025 Financial Results, Details on Revenue and Profit Margins Pending January 29, 2025 | 7:39 p.m. IST
Cipla Shares Q3 FY25 Earnings Call Recording, Complies With SEBI Disclosure Norms January 28, 2025 | 8:30 p.m. IST
Cipla Reports Q3 FY2025 Revenue of ₹7,072.97 Cr and Net Profit of ₹1,574.59 Cr, Driven by Strong Growth January 28, 2025 | 7:02 p.m. IST
Cipla Elevates Achin Gupta to Global COO, Effective February 1, 2025 January 28, 2025 | 2:38 p.m. IST
Cipla Elevates Achin Gupta To Global COO, Effective February 2025 January 28, 2025 | 2:37 p.m. IST
Cipla Reports Record Quarterly Revenue of ₹7,073 Cr with 50% Surge in Profit After Tax for Q3 FY25 January 28, 2025 | 2:27 p.m. IST
Cipla Reports 16% Revenue Growth in Q3FY25, With PAT Soaring to ₹1,571 Cr and EBITDA Up 50% January 28, 2025 | 2:13 p.m. IST
Cipla Reports Q3 FY2025 Revenue of ₹7,072.97 Cr and Net Profit of ₹1,574.59 Cr, Driven by Strong Growth January 28, 2025 | 2:01 p.m. IST
Cipla's Global Chief Manufacturing Officer Rajeev Kumar Sinha Resigns, Last Day on April 2, 2025 January 23, 2025 | 6:11 p.m. IST
Cipla Reports USFDA Inspection at Medispray Facility, Receives One Observation January 20, 2025 | 7:39 p.m. IST